VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (1218)	6/16/1997 5:28:00 PM
From: Pseudo Biologist	of 9719

Vector, the introductions to these two papers talk about rate of succes of standard chemo in low-, intermediate and high-grade NHL (they go on to talk about other strategies to treat NHL): Lancet 349, 1137 (1997), and Ann Oncology 5 Suppl 1 67-70 (1994). The Coulter investor pack includes reports by analysts from Alex Brown, Pacific and one more. I think at least one of them uses the $10K figure per patient you quote (or something very close to it). The early responses do look good and to this unstatistical eye look better than IDEC's (with the caveat of numbers of patients and possibly different definitions of end points). Brad (see his posts in TCLN's board) cites a 60-65% of intermediate- and high-grade NHL for new cases out of an ASCO conference or report. I think one or more of the documents included with CLTR's packet contains numbers consistent (within 10 % points) with the above figures. Max

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next